There are large individual differences among humans and animals in behavioral, physiological and toxicological responses to drugs of abuse. Many of these individual differences in behavioral responses to drugs display substantial genetic components. Transgenic animals provide means for approaching several interrelated goals: 1)Ascertainment of biochemical and behavioral consequences of the introduction of or disruption of specific genes; 2)Ascertainment of the consequences of over- or under-expressing candidate genes identified in human studies; 3) Elucidation of gene elements yielding cell-type specific expression and trans-synaptic gene regulation; 4) Studying influences of interactions between variants at different genomic loci; 5)Elucidating haplotype-specific levels of expression differences in vivo, expecially when currently-available cultured cell models are not optimal. Influences of human allelic variations and dopamine systems in mechanisms of reward, reinforcement and learning have led to continuing focus on these systems during this year. In continuing studies of combined transporter and transporter/receptor knockouts, we have obtained novel data concerning the relationship between expression of each of these gene products at normal levels and drug-induced behavioral changes. In studies of variations at candidate gene loci determined from human studies, we have identified striking effects of cocaine reward in mice with altered levels of expression of BDNF and NrCAM. We have characterized mice with deletions of an """"""""orphan"""""""" transporter vt-3 and identified its role in uptake of proline and leucine in brain synaptosomes, as well as the ability of other uptake systems to compensate for any effects of its constutuitive deletion on a variety of behaviors.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Intramural Research (Z01)
Project #
1Z01DA000165-11
Application #
7320345
Study Section
(MNRB)
Project Start
Project End
Budget Start
Budget End
Support Year
11
Fiscal Year
2006
Total Cost
Indirect Cost
Name
National Institute on Drug Abuse
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Uhl, George R; Drgonova, Jana; Hall, F Scott (2014) Curious cases: Altered dose-response relationships in addiction genetics. Pharmacol Ther 141:335-46
Kitanaka, Nobue; Kitanaka, Junichi; Hall, F Scott et al. (2008) Alterations in the levels of heterotrimeric G protein subunits induced by psychostimulants, opiates, barbiturates, and ethanol: Implications for drug dependence, tolerance, and withdrawal. Synapse 62:689-99
Ide, Soichiro; Minami, Masabumi; Ishihara, Kumatoshi et al. (2008) Abolished thermal and mechanical antinociception but retained visceral chemical antinociception induced by butorphanol in micro-opioid receptor knockout mice. Neuropharmacology 54:1182-8
Perona, Maria T G; Waters, Shonna; Hall, Frank Scott et al. (2008) Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. Behav Pharmacol 19:566-74
Onaivi, Emmanuel S; Ishiguro, Hiroki; Gong, Jian-Ping et al. (2008) Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS ONE 3:e1640
Uhl, George R; Drgon, Tomas; Johnson, Catherine et al. (2008) ""Higher order"" addiction molecular genetics: convergent data from genome-wide association in humans and mice. Biochem Pharmacol 75:98-111
Seeman, Philip; Hall, Frank Scott; Uhl, George (2007) Increased dopamine D2High receptors in knockouts of the dopamine transporter and the vesicular monoamine transporter may contribute to spontaneous hyperactivity and dopamine supersensitivity. Synapse 61:573-6
Fukushima, Setsu; Shen, Haowei; Hata, Harumi et al. (2007) Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant mice. Psychopharmacology (Berl) 193:55-62
Yamamoto, Hideko; Kamegaya, Etsuko; Hagino, Yoko et al. (2007) Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture. Neurochem Int 51:237-44
Uhl, George (2007) Premature poking: impulsivity, cocaine and dopamine. Nat Med 13:413-4

Showing the most recent 10 out of 47 publications